Danny Crawford

Danny Crawford is a highly experienced professional in the biochemistry and biotechnology sectors, currently serving as Senior Director of Early-Stage Process Development at Intellia Therapeutics, Inc. since May 2017. Key responsibilities include leading the Nucleic Acid Process Sciences team and overseeing late-stage process development for mRNA constructs. Previous roles at Intellia include Director and Associate Director positions in Nucleic Acid Process Sciences, where significant contributions were made to analytical control strategies for drug substances. Prior experience includes roles at Translate Bio and Shire Pharmaceuticals, focused on RNA analytical techniques, as well as postdoctoral and doctoral research at the University of Pennsylvania and Brandeis University, respectively, where innovative methodologies in mass spectrometry and single-molecule fluorescence techniques were developed. Crawford holds a PhD in Biochemistry from Brandeis University and a Bachelor of Science in Chemistry from the Massachusetts Institute of Technology.